Therapeutic Strategies in the Guillain-Barré Syndrome

Bernd C. Kieseier; Hans-Peter Hartung

doi:10.1055/s-2003-41132

Seminars in Neurology, Table of Contents

Semin Neurol 2003; 23(2): 159-168
DOI: 10.1055/s-2003-41132

Therapeutic Strategies in the Guillain-Barré Syndrome

Bernd C. Kieseier, Hans-Peter Hartung

Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany

Abstract

ABSTRACT

The Guillain-Barré syndrome (GBS) represents the prototypic immune-mediated peripheral neuropathy, which is now recognized as a group of conditions with diverse pathology and pathogenesis. The observation that plasma exchange and intravenous immunoglobulin result in clinical improvement, the presence of circulating antibodies targeting structures on peripheral nerve tissue in sera from GBS patients, and the deposition of immunoglobulins and complement demonstrated on myelinated fibers in nerve biopsies from affected patients point to a critical role of the humoral immune response in the pathogenesis of GBS. However, the observation of inflammatory infiltrates in nerve and the critical pathogenic role of neuritogenic T lymphocytes as demonstrated in the animal model support the concept that a disordered cellular immunity is also of critical importance in the pathogenesis of this neuropathy. Current treatment strategies are aimed at mitigating the harmful effects of the immune system on peripheral nerve. This review will address the rationale for immunotherapy in GBS based on experimental and immunologic studies of the pathogenesis of this disease.

KEYWORDS

Guillain-Barré - syndrome - plasma exchange - intravenous immunoglobulins - molecular mimicry

Full Text

References

REFERENCES

1 Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr Opin Neurol . 2001; 14 605-613
2 Hartung H-P, Pollard J D, Harvey G K, Toyka K V. Invited review: immunopathogenesis and treatment of the Guillain-Barré syndrome, part I and II. Muscle Nerve . 1995; 18 137-164
3 Hahn A F. Guillain-Barré syndrome. Lancet . 1998; 352 635-641
4 Hughes R AC. The concept and classification of Guillain-Barré syndrome and related disorders. Rev Neurol (Paris) . 1995; 151 291-294
5 Van der Meche G F, Van Doorn A P, Meulstee J, Jennekens F G. Diagnostic and classification criteria for the Guillain-Barré syndrome. Eur Neurol . 2001; 45 133-139
6 Willison H J, O'Hanlon G M. The immunopathogenesis of Miller Fisher syndrome. J Neuroimmunol . 1999; 100 3-12
7 Winer J B. Guillain Barré syndrome. Mol Pathol . 2001; 54 381-385
8 Hartung H-P, Willison H, Kieseier B C. Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr Opin Neurol . 2002; 15 571-577
9 Griffin J W, Li C Y, Ho T W. et al . Guillain-Barré syndrome in northern China: the spectrum of neuropathological changes in clinically defined cases. Brain . 1995; 118 577-595
10 Griffin J W, Li C Y, Ho T W. et al . Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol . 1996; 39 17-28
11 Jacobs B C, Rothbarth P H, van der Meche G F. et al . The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology . 1998; 51 1110-1115
12 Tsang R S. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome. Curr Opin Infect Dis . 2002; 15 221-228
13 Hadden R D, Karch H, Hartung H P. et al . Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurology . 2001; 56 758-765
14 Gold R, Archelos J J, Hartung H P. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol . 1999; 9 343-360
15 Yuki N. Infectious origins of, and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect Dis . 2001; 1 29-37
16 Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology . 1993; 43 1911-1917
17 O'Leary C P, Willison H J. The role of antiglycolipid antibodies in peripheral neuropathies. Curr Opin Neurol . 2000; 13 583-588
18 Gabriel C M, Gregson N A, Hughes R A. Anti-PMP22 antibodies in patients with inflammatory neuropathy. J Neuroimmunol . 2000; 104 139-146
19 Kwa M S, van Schaik N I, Brand A, Baas F, Vermeulen M. Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. J Neuroimmunol . 2001; 116 220-225
20 Willison H J, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain . 2002; 125 2591-2625
21 Koga M, Ang C W, Yuki N. et al . Comparative study of preceding Campylobacter jejuni infection in Guillain-Barré syndrome in Japan and The Netherlands. J Neurol Neurosurg Psychiatry . 2001; 70 693-695
22 Ang C W, Koga M, Jacobs B C, Yuki N, van der Meche G F, van Doorn A P. Differential immune response to gangliosides in Guillain-Barré syndrome patients from Japan and The Netherlands. J Neuroimmunol . 2001; 121 83-87
23 Ang C W, De Klerk A M, Endtz H P. et al . Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. Infect Immun . 2001; 69 2462-2469
24 Jacobs B C, van Doorn A P, Schmitz P IM. et al . Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol . 1996; 40 181-187
25 Yuki N, Ang C W, Koga M. et al . Clinical features and response to treatment in Guillain-Barré syndrome associated with antibodies to GM1b ganglioside. Ann Neurol . 2000; 47 314-321
26 Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol . 2000; 48 624-631
27 Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K. Anti-GalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann Neurol . 1999; 45 758-768
28 Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology . 1990; 40 1900-1902
29 Odaka M, Yuki N, Hirata K. Anti-GQ1b IgG antibody syndrome: clinical and immunological range. J Neurol Neurosurg Psychiatry . 2001; 70 50-55
30 Yoshino H, Harukawa H, Asano A. IgG antiganglioside antibodies in Guillain-Barré syndrome with bulbar palsy. J Neuroimmunol . 2000; 105 195-201
31 Koga M, Yuki N, Takahashi M, Saito K, Hirata K. Are Campylobacter curvus and Campylobacter upsaliensis antecedent infectious agents in Guillain-Barré and Fisher's syndromes?. J Neurol Sci . 1999; 163 53-57
32 Gong Y, Tagawa Y, Lunn M P. et al . Localization of major gangliosides in the PNS: implications for immune neuropathies. Brain . 2002; 125 2491-2506
33 Paparounas K, O'Hanlon G M, O'Leary C P, Rowan E G, Willison H J. Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro. Brain . 1999; 122 807-816
34 Plomp J J, Molenaar P C, O'Hanlon G M. et al . Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol . 1999; 45 189-199
35 Goodyear C S, O'Hanlon G M, Plomp J J. et al . Monoclonal antibodies raised against Guillain-Barré syndrome-associated Campylobacter jejuni lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. J Clin Invest . 1999; 104 697-708
36 O'Hanlon G M, Plomp J J, Chakrabarti M. et al . Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain . 2001; 124 893-906
37 Buchwald B, Weishaupt A, Toyka K V, Dudel J. Pre- and postsynaptic blockade of neuromuscular transmission by Miller-Fisher syndrome IgG at mouse motor nerve terminals. Eur J Neurosci . 1998; 10 281-290
38 Plomp J J, Molenaar P C, O'Hanlon G M. et al . Miller Fisher anti-GQ1b antibodies: alpha-latrotoxin-like effects on motor end plates. Ann Neurol . 1999; 45 189-199
39 Buchwald B, Bufler J, Carpo M. et al . Combined pre- and postsynaptic action of IgG antibodies in Miller Fisher syndrome. Neurology . 2001; 56 67-74
40 Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann Neurol . 1996; 39 424-431
41 Yuki N, Yamada M, Koga M. et al . Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 gangliosides. Ann Neurol . 2001; 49 712-720
42 Hadden R D, Gregson N A, Gold R, Willison H J, Hughes R A. Guillain-Barré syndrome serum and anti-Campylobacter antibody do not exacerbate experimental autoimmune neuritis. J Neuroimmunol . 2001; 119 306-316
43 Gold R, Hartung H P, Toyka K V. Animal models for autoimmune demyelinating disorders of the nervous system. Mol Med Today . 2000; 6 88-91
44 Khalili-Shirazi A, Gregson N A, Hall M A, Hughes R A, Lanchbury J S. T cell receptor V beta gene usage in Guillain-Barré syndrome. J Neurol Sci . 1997; 145 169-176
45 Khalili-Shirazi A, Gregson N, Hughes R. CD1 expression in human peripheral nerve of GBS patients. Biochem Soc Trans . 1997; 25 172S
46 Cooper J C, Ben-Smith A, Savage C O, Winer J B. Unusual T cell receptor phenotype V gene usage of gamma delta T cells in a line derived from the peripheral nerve of a patient with Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry . 2000; 69 522-524
47 Previtali S C, Feltri M L, Archelos J J, Quattrini A, Wrabetz L, Hartung H. Role of integrins in the peripheral nervous system. Prog Neurobiol . 2001; 64 35-49
48 Previtali S C, Archelos J J, Hartung H P. Expression of integrins in experimental autoimmune neuritis and Guillain-Barré syndrome. Ann Neurol . 1998; 44 611-621
49 Kieseier B C, Tani M, Mahad D. et al . Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain . 2002; 125 823-834
50 Kieseier B C, Kiefer R, Clements J M. et al . Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain . 1998; 121 159-166
51 Mueller M, Wacker K, Ringelstein E B, Hickey W F, Imai Y, Kiefer R. Rapid response of identified resident endoneurial macrophages to nerve injury. Am J Pathol . 2001; 159 2187-2197
52 Kiefer R, Kieseier B C, Stoll G, Hartung H-P. The role of macrophages in immune-mediated damage to the peripheral nervous system. Prog Neurobiol . 2001; 64 109-127
53 Raphael J C, Chevret S, Hughes R A, Annane D. Plasma exchange for Guillain-Barré syndrome (Cochrane Review). Cochrane Database Syst Rev . 2001; 2 CD001798
54 Hughes R A, Raphael J C, Swan A V, van Doorn A P. Intravenous immunoglobulin for Guillain-Barré syndrome (Cochrane Review). Cochrane Database Syst Rev . 2001; 2 CD002063
55 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet . 1997; 349 225-230
56 The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology . 1985; 35 1096-1104
57 French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Efficacy of plasma exchange in Guillain-Barré Syndrome. Ann Neurol . 1987; 22 753-761
58 van der Meche G F, Schmitz P I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med . 1992; 326 1123-1129
59 Bril V, Ilse W K, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology . 1996; 46 100-103
60 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol . 1997; 41 298-306
61 Hughes R A, van Der Meche G F. Corticosteroids for treating Guillain-Barré syndrome. Cochrane Database Syst Rev . 2000; 3 CD001446
62 Wollinsky K H, Hulser P J, Brinkmeier H. et al . CSF filtration is an effective treatment of Guillain-Barré syndrome: a randomized clinical trial. Neurology . 2001; 57 774-780
63 Brinkmeier H, Aulkemeyer P, Wollinsky K H, Rudel R. An endogenous pentapeptide acting as a sodium channel blocker in inflammatory autoimmune disorders of the central nervous system. Nat Med . 2000; 6 808-811
64 Feasby T E, Hartung H P. Drain the roots: a new treatment for Guillain-Barré syndrome?. Neurology . 2001; 57 753-754
65 Raphael J C, Chevret S, Harboun M, Jars-Guincestre M C. Intravenous immune globulins in patients with Guillain-Barré syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry . 2001; 71 235-238
66 Visser L H, Van der Meche G F, Van Doorn A P. et al . Guillain-Barré syndrome without sensory loss (acute motor neuropathy): a subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barré Study Group. Brain . 1995; 118 841-847
67 Jacobs BC, van Doorn A P, Schmitz P I. et al . Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome. Ann Neurol . 1996; 40 181-187
68 Diegel M L, Rankin B M, Bolen J B, Dubois P M, Kiener P A. Cross-linking of Fc gamma receptor to surface immunoglobulin on B cells provides an inhibitory signal that closes the plasma membrane calcium channel. J Biol Chem . 1994; 269 11409-11416
69 Kondo N, Kasahara K, Kameyama T. et al . Intravenous immunoglobulins suppress immunoglobulin productions by suppressing Ca(2+)-dependent signal transduction through Fc gamma receptors in B lymphocytes. Scand J Immunol . 1994; 40 37-42
70 Lacroix-Desmazes S, Kaveri S V, Mouthon L. et al . Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods . 1998; 216 117-137
71 Lutz H U, Stammler P, Jelezarova E, Nater M, Spath P J. High doses of immunoglobulin G attenuate immune aggregate-mediated complement activation by enhancing physiologic cleavage of C3b in C3bn-IgG complexes. Blood . 1996; 88 184-193
72 Imbach P, Barandun S, d'Apuzzo V. et al . High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet . 1981; 1 1228-1231
73 Stangel M, Compston A. Polyclonal immunoglobulins (IVIg) modulate nitric oxide production and microglial functions in vitro via Fc receptors. J Neuroimmunol . 2001; 112 63-71
74 Marchalonis J J, Kaymaz H, Dedeoglu F, Schluter S F, Yocum D E, Edmundson A B. Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci U S A . 1992; 89 3325-3329
75 Vassilev T L, Kazatchkine M D, Van Huyen P J. et al . Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood . 1999; 93 3624-3631
76 Viard I, Wehrli P, Bullani R. et al . Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science . 1998; 282 490-493
77 Buchwald B, Ahangari R, Weishaupt A, Toyka K V. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann Neurol . 2002; 51 673-680
78 Dalakas M C. Blockade of blocking antibodies in Guillain-Barré syndrome: "unblocking" the mystery of action of intravenous immunoglobulin. Ann Neurol . 2002; 51 667-668
79 Créange A, Lerat H, Meyrignac C, Degos J-D, Gherardi R K, Cesaro P. Treatment of Guillain-Barré syndrome with interferon-b. Lancet . 1998; 352 368-369
80 Schaller B, Radziwill A J, Steck A. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-b-1a and intravenous immunoglobulin. Eur Neurol . 2001; 46 167-168
81 Korn T, Toyka K, Hartung H P, Jung S. Suppression of experimental autoimmune neuritis by leflunomide. Brain . 2001; 124 1791-1802
82 Kieseier B C, Krivacic K, Jung S. et al . Sequential expression of chemokines in experimental autoimmune neuritis. J Neuroimmunol . 2000; 110 121-129
83 Archelos J J, Previtali S C, Hartung H P. The role of integrins in immune-mediated diseases of the nervous system. Trends Neurosci . 1999; 22 30-38
84 Kieseier B C, Seifert T, Giovannoni G, Hartung H P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology . 1999; 53 20-25
85 Bensa S, Hadden R D, Hahn A, Hughes R A, Willison H J. Randomized controlled trial of brain-derived neurotrophic factor in Guillain-Barré syndrome: a pilot study. Eur J Neurol . 2000; 7 423-426